Speaker Profile
M.D., VP, Daiichi Sankyo
Biography
Peter is a medical oncologist and an oncology drug developer with 17 years of oncology drug development experience, 15 years in the industry. He currently oversees Late-Stage Oncology Development at DSI, and previously held the role of VP, Section Head of GU Oncology at Merck Inc. Over his tenure, Peter was responsible for the clinical development and approval of multiple important medicines, including Keytruda and Enhertu, for melanoma, MSI-H tumors, and a wide range of other cancers such as esophageal, gastric, pancreatic, renal cell, urothelial, prostate, breast, and lung cancers.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• S. Peter Kang, Daiichi Sankyo
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Jedd D. Wolchok, Weill Cornell Medicine
Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Biomarker Decision Gates
• Chair: Levi Garraway, Roche
